(secondQuint)CP4071 in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma.

 OBJECTIVES: - Determine the efficacy, in terms of response rate, of CP4071 in patients with previously treated, locally advanced or metastatic soft tissue sarcoma.

 - Determine the clinical toxic effects of this drug in these patients.

 OUTLINE: Patients receive oral CP4071 daily.

 Treatment continues in the absence of disease progression or unacceptable toxicity.

 PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study.

.

 CP4071 in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma@highlight

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

 PURPOSE: Phase II trial to study the effectiveness of CP4071 in treating patients who have locally advanced or metastatic soft tissue sarcoma.

